Chimeric Therapeutics (ASX: CHM) shares encouraging in vitro data for next-gen NK cell platform

August 17, 2023 01:30 PM AEST | By Team Kalkine Media

Google News:

Chimeric Therapeutics (ASX: CHM) shares encouraging in vitro data for next-gen NK cell platform — Image source: Company website

Recent News

Mizuho remains bullish on data centers; DLR remains top pick

Macquarie Group’s Role in the Expanding Australia Share Market

Middle East Tensions Impact Australian Share Market Performance

Impact Minerals (ASX:IPT) Unveils Promising Lake Hope HPA Project in L...

Highlights

Chimeric has reported positive in vitro data for its next generation armored natural killer (NK) cell platform, CHM 0301.

CHM 0301 has presented significant enhancement of TGFβ resistance and potency.

Chimeric is focused on further advancing its CHM 1301 platform and initiating work on its lead CAR NK programs for solid tumours.

Chimeric Therapeutics Limited (ASX: CHM) has shared encouraging in vitro data for CHM 0301, the company’s next generation armored natural killer (NK) cell platform.

The ASX-listed cell therapy-focused company collaborated with the laboratory of Dr Wald under a sponsored research program in November 2022. Under the collaboration, Chimeric and Dr Wald’s team designed, produced, and characterised CHM 0301 to maximise potency and increase the resistance of CHM 0201 NK cells to TGFβ.

The CHM 0301 platform has been developed on the base of CHM 0201, which has earlier shown safety and early signs of clinical activity in patients with acute myeloid leukemia (AML) and colorectal cancer (CRC). Currently, it is being assessed in the first clinical trial to integrate NK cells with Vactosertib, an oral TGFβ receptor inhibitor.

Details of positive in vitro data

The platform was assessed in in vitro models of CRC and AML. The platform presented substantial improvement in TGFβ resistance and potency in comparison to CHM 0201 cells, suggests the company update.

Data Source: Company update

The company highlighted that more experiments are being conducted to characterise the activity and behaviour of the cell platform. As a part of the CHM 1301 and CHM 2301 CAR NK programs, the company intends to introduce CLTX and CDH17 CARs into its NK cell platform.

CHM 0301 engineers CHM 0201 cells with two “armoring” enhancements, created with the aim to increase potency and control immune-suppressive tumour microenvironments.

The CHM 0301 cells secrete the immunostimulatory cytokine interleukin 15 and demonstrate a dominant-negative TGFβ receptor molecule on the surface.

TGFβ is a key immune-suppressive factor that is expressed in the tumour microenvironment and known to inhibit the anti-tumour activity of NK cells and T cells.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.